amobarbital has been researched along with Prolymphocytic Leukemia in 1 studies
Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gamen, S | 1 |
| Anel, A | 1 |
| Montoya, J | 1 |
| Marzo, I | 1 |
| Piñeiro, A | 1 |
| Naval, J | 1 |
1 other study available for amobarbital and Prolymphocytic Leukemia
| Article | Year |
|---|---|
mtDNA-depleted U937 cells are sensitive to TNF and Fas-mediated cytotoxicity.
Topics: Amobarbital; Antibodies; Apoptosis; Base Sequence; Cell Division; Cell Line; DNA, Mitochondrial; Doc | 1995 |